eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1/2005
vol. 1
 
Share:
Share:
more
 
 
abstract:

REVIEW PAPER/EDITORIAL
Tumor Necrosis Factor alpha receptors p55 and p75 and ovarian cancer – state-of-the-art research and clinical implications

Paweł Rzymski

Arch Med Sci 2005; 1, 1: 3-7
Online publish date: 2005/05/06
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Tumor Necrosis Factor a acts via its two cell-surface receptors p55 and p75 and the effect depends on their activation. Receptors are proteins that dissociate from cell surface and become soluble molecules in serum blocking the natural activity of TNFα. It has been proved that this cytokine and both receptors could be overexpressed and constitutively produced by many malignant tumors, including ovarian cancer. However, little is known about the ovarian-specific role in cancer biology. Molecular and immunological research was not followed by many clinical evaluations of potential power of TNFα, p55 and p75. Some research supports previous laboratory results. It has been also suggested that especially receptors p55 and p75 could be useful in ovarian cancer detection, differentiation, staging or predicting prognosis, relapse and surgical debulking. Results are inspiring and promising, but should be followed by more well-designed research.
keywords:

TNF alpha receptors, CD120a, CD120b, tumor markers, ovarian cancer

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe